Kosho Yamanouchi1, Sayaka Kuba2, Chika Sakimura2, Michi Morita2, Kengo Kanetaka2, Kazuma Kobayashi2, Mitsuhisa Takatsuki2, Naomi Hayashida3, Susumu Eguchi2. 1. Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan ymanouch@gk9.so-net.ne.jp. 2. Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 3. Division of Strategic Collaborative Research, Center for Promotion of Collaborative Research on Radiation and Environment Health Effects, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Abstract
BACKGROUND/AIM: Docetaxel often induces peripheral neuropathy (PN). The aim of this study was to elucidate the relationship between PN and systemic inflammation parameters, namely the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). PATIENTS AND METHODS: We retrospectively evaluated 67 patients with breast cancer who were treated with docetaxel. Thirty patients (44.8%) had received previous chemotherapy including anthracycline. RESULTS: Overall, 51 patients (76.1%) experienced PN. All the parameters increased with the number of administered courses of docetaxel. In an analysis of patients without previous chemotherapy, those suffering from PN had a significantly higher NLR at the first and third cycles than those not suffering from PN (2.9 vs. 2.0, and 3.1 vs. 2.6, respectively, both p<0.05), and the MLR at the first cycle was also significantly higher in those with PN than in those without (0.18 vs. 0.15, p<0.05). CONCLUSION: Systemic inflammation appears to contribute to the occurrence of PN induced by docetaxel. Copyright
BACKGROUND/AIM: Docetaxel often induces peripheral neuropathy (PN). The aim of this study was to elucidate the relationship between PN and systemic inflammation parameters, namely the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). PATIENTS AND METHODS: We retrospectively evaluated 67 patients with breast cancer who were treated with docetaxel. Thirty patients (44.8%) had received previous chemotherapy including anthracycline. RESULTS: Overall, 51 patients (76.1%) experienced PN. All the parameters increased with the number of administered courses of docetaxel. In an analysis of patients without previous chemotherapy, those suffering from PN had a significantly higher NLR at the first and third cycles than those not suffering from PN (2.9 vs. 2.0, and 3.1 vs. 2.6, respectively, both p<0.05), and the MLR at the first cycle was also significantly higher in those with PN than in those without (0.18 vs. 0.15, p<0.05). CONCLUSION: Systemic inflammation appears to contribute to the occurrence of PN induced by docetaxel. Copyright
Authors: Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto Journal: Br J Pharmacol Date: 2020-06-03 Impact factor: 8.739
Authors: David Mizrahi; Susanna B Park; Tiffany Li; Hannah C Timmins; Terry Trinh; Kimberley Au; Eva Battaglini; David Wyld; Robert D Henderson; Peter Grimison; Helen Ke; Peter Geelan-Small; Julie Marker; Brian Wall; David Goldstein Journal: JAMA Netw Open Date: 2021-02-01
Authors: Ian R Kleckner; Todd A Jusko; Eva Culakova; Kaitlin Chung; Amber S Kleckner; Matthew Asare; Julia E Inglis; Kah Poh Loh; Luke J Peppone; Jessica Miller; Marianne Melnik; Samer Kasbari; Deborah Ossip; Karen M Mustian Journal: Breast Cancer Res Treat Date: 2021-06-30 Impact factor: 4.624